Updates are available Correction dated 2018-12-19
Click to view Correction: https://doi.org/10.1038/s41581-018-0102-7
-
Authors
Leung, Nelson http://orcid.org/0000-0002-5651-1411
Bridoux, Frank
Batuman, Vecihi
Chaidos, Aristeidis
Cockwell, Paul
D’Agati, Vivette D.
Dispenzieri, Angela
Fervenza, Fernando C.
Fermand, Jean-Paul
Gibbs, Simon
Gillmore, Julian D.
Herrera, Guillermo A.
Jaccard, Arnaud
Jevremovic, Dragan
Kastritis, Efstathios
Kukreti, Vishal
Kyle, Robert A.
Lachmann, Helen J.
Larsen, Christopher P.
Ludwig, Heinz
Markowitz, Glen S.
Merlini, Giampaolo
Mollee, Peter
Picken, Maria M.
Rajkumar, Vincent S.
Royal, Virginie
Sanders, Paul W. http://orcid.org/0000-0002-2915-5714
Sethi, Sanjeev http://orcid.org/0000-0002-4536-7709
Venner, Christopher P.
Voorhees, Peter M.
Wechalekar, Ashutosh D.
Weiss, Brendan M.
Nasr, Samih H.
- License Information
-
More Information
Article History
First Online: 3 December 2018
Competing interests
: N.L. declares that he is a member of the advisory boards of BTG International, Prothena and Takeda; has received trial support from Omeros; and consults for Aduro. F.B. declares that he has received honoraria from Celgene and Janssen. P.C. declares that he is a member of the advisory board of The Binding Site, receives research support from The Binding Site and has received honoraria from Janssen. A.D. declares that she has received research grants from Alnylam, Celgene, GlaxoSmithKline, Janssen, Pfizer, Prothena and Takeda. F.C.F. declares that he has received an unrestricted grant from Genentech and Janssen and is a member of the advisory board for Alnylam. J.D.G. declares that he is a member of the advisory boards for Alnylam, Eidos and GlaxoSmithKline. V.K. declares that he has received honoraria from Amgen, Celgene and Takeda. H.J.L. declares that she has received research funding from Amgen and Takeda and is a member of the speaker’s bureau for Amgen, Bristol-Myers Squibb, Celgene, Janssen and Takeda. H.L. declares that he has received research support from Amgen and Takeda and is a member of the speaker’s bureau for Amgen, Bristol-Myers Squibb, Celgene, Janssen and Takeda and consults for PharmaMar. G.M. declares that he has received honoraria from Janssen, Pfizer and Prothena. P.M. declares that he is a member of the advisory boards of Amgen, Celgene and Janssen and has received clinical trial support from Janssen. S.H.N declares that he has received honoraria from Alnylam. C.P.V. declares that he has received honoraria from Amgen, Celgene, Janssen, Prothena and Takeda. P.M.V. declares that he is a member of the advisory boards of Bristol-Myers Squibb, Celgene, Janssen, Oncopeptides and TeneoBio and is a member of the speaker’s bureau for Amgen and Janssen and consults for Celgene, Novartis, Oncopeptides and TeneoBio. B.M.W. declares that in October 2017 he became an employee of Janssen. All other authors declare no competing interests.
